Login to Your Account

Teva Outbids Valeant for Cephalon in $6.8B Cash Offer

By Catherine Shaffer

Tuesday, May 3, 2011
Jerusalem's Teva Pharmaceutical Industries Ltd., announced this morning that it will acquire Frazer, Pa.-based Cephalon Inc. for $6.8 billion in cash, trumping Valeant Pharmaceutical International Inc.'s recent hostile bid of $5.7 billion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription